Statement from Beth Battaglino, RN-C CEO, HealthyWomen, regarding access to oral birth control: The FDA approval of the first over-the-counter (OTC) progestin-only oral contraception, Opill, is […]
Statement from Beth Battaglino, RN-C CEO, HealthyWomen, regarding access to oral birth control: The FDA approval of the first over-the-counter (OTC) progestin-only oral contraception, Opill, is […]